An overview of the global market for infectious disease treatments, with a
focus on the growth in demand for newer pharmaceutical treatments, vaccines,
and environmental products
Analyses of global market trends, with data from 2011 and 2012, and
projections of compound annual growth rates (CAGRs) through 2017
Discussion of the increasing concern regarding antibiotic-resistant
organisms and their sometimes-fatal effects on humans
Examination of technological developments, future trends, and emerging
opportunities
Assessments of the current state of infectious diseases on a global basis,
broken down by type of disease (i.e., bacterial, viral, parasitic, and fungal)
and appropriate treatments, both current and anticipated, and by geographic
region
Patent analysis
Comprehensive company profiles of major players.
REPORT SCOPE
INTRODUCTION
STUDY GOALS AND OBJECTIVES
Infectious diseases are one of the major causes of global morbidity and
mortality. Viral, bacterial, parasitic and fungal diseases have plagued
humankind for centuries, and our attempts to control these diseases have met
with great success. Diseases that were once death sentences are now chronic
and manageable diseases.
But as with every ongoing story, microbes have transformed themselves to
outwit current medications, and the battle to rid humans of the most virulent
of diseases continues. With the constant combining and reinvention of
microbes comes an urgent need for improved antibiotic and viral medications to
sustain the progress made in addressing the most aggressive of infectious
diseases.
Under these circumstances, there is need for a current and comprehensive
report on infectious diseases covering diagnosis, treatment, demand trends,
opportunities, and emerging technologies.
This study gives a clear, quantitative picture of the supply-and-demand
scenario, and it highlights the technological and investment opportunities in
the field.
REASONS FOR DOING THE STUDY
This report provides the reader with a detailed analysis of the global
infectious disease market, with emphasis on seven major infectious diseases
(i.e., human immunodeficiency virus/acquired immunodeficiency virus
[HIV/AIDS]; hepatitis A, B, C; malaria, rotavirus/diarrhea; measles;
pneumonia; and tuberculosis [TB]).
The report also discusses technological developments, future trends, and
emerging opportunities. The major objectives of this study are:
Assessing the current state of infectious diseases on a global basis.
Identifying the driving factors for demand of new diagnostic and
pharmaceutical products.
Estimating current and future market sizes for diagnostic and
pharmaceutical infectious disease products.
Estimating the current global supply-and-demand scenario, by disease type
and geographical regions.
Identifying factors that influence the industry and proposing market
opportunities.
SCOPE OF REPORT
The market report organizes information from diverse sources into a cohesive
unit that includes an overview, global implications of infectious diseases,
infectious diseases by type, treatment and prevention, emerging pharmaceutical
and diagnostic products, and an applicable patents section. Information is
organized by type of infectious disease (i.e., bacterial, viral, parasitic)
and appropriate treatments, both current and anticipated.
INTENDED AUDIENCE
This updated version on the infectious disease market and technologies will be
a valuable tool for decision makers and manufacturers in both the diagnostic
and the pharmaceutical treatment industries. Individuals at research
foundations, manufacturing companies, and university laboratories will find
valuable information on the global diagnostic product and pharmaceutical
industries. This information will also be useful for individuals involved in
strategic planning and marketing and sales development.
The audience will obtain a broad view of the social and economic consequences
of infectious diseases. Additionally, emphasis on the type of disease, major
players in the marketplace, market conditions, and current and projected
revenues will be provided.
METHODOLOGIES AND INFORMATION SOURCES
The data for this report were gathered from primary and secondary sources.
Sources include information obtained from industry analysis, manufacturers,
academic and trade journals, and industry associations. Additional sources
include the U.S. Patent and Trademark Office (USPTO), U.S. Securities and
Exchange Commission (SEC) filings, the World Health Organization (WHO), the
Centers for Disease Control (CDC), the Mayo Clinic, the Pharmaceutical
Research and Manufacturing Association, and UNAIDS.
Where precise information was not available, a projection was made using
reasonable assumptions and estimates based on historical data. All market data
are based on manufacturers' sales.
ANALYST CREDENTIALS
Peggy Lehr is the BCC Research analyst for this report. Ms. Lehr holds a BS in
Journalism from the University of Colorado, Boulder, and an MS in
Communication from the University of Denver. Ms. Lehr has worked as a
researcher, editor, and publisher within the publishing industry for both
for-profit and not-for-profit organizations. She is the author of several BCC
reports dealing with healthcare, pharmaceuticals, and agriculture.
Table of Contents
Table of Contents
Chapter- 1: INTRODUCTION - Complimentary
STUDY GOALS AND OBJECTIVES
REASONS FOR DOING THE STUDY
SCOPE OF REPORT
INTENDED AUDIENCE
METHODOLOGIES AND INFORMATION SOURCES
ANALYST CREDENTIALS
RELATED BCC REPORTS
BCC ON-LINE SERVICES
DISCLAIMER
Chapter- 2: SUMMARY
Table Summary : PROJECTED MARKET FOR INFECTIOUS DISEASES DIAGNOSTIC,
VACCINE AND PHARMACEUTICAL PRODUCTS BY TYPE, THROUGH 2017
Figure Summary : PERCENTAGE OF MARKET SHARE FOR INFECTIOUS DISEASE
DIAGNOSTIC, VACCINE AND PHARMACEUTICAL PRODUCTS BY GEOGRAPHIC REGION, 2012 AND
2017
Chapter- 3: OVERVIEW OF THE GLOBAL STATE OF INFECTIOUS DISEASE DIAGNOSIS, VACCINES, AND TREATMENT
TOP GLOBAL CAUSES OF DEATH
MAJOR INFECTIOUS DISEASES
HISTORICAL IMPACT OF INFECTIOUS DISEASES
TREATMENTS FOR INFECTIOUS DISEASES
GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET
TYPES OF DIAGNOSTIC TESTING
GLOBAL MARKET FOR INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS
GLOBAL INFECTIOUS DISEASE VACCINE MARKET
THE GLOBAL INFECTIOUS DISEASE PHARMACEUTICAL MARKET
PROJECTIONS FOR GLOBAL INFECTIOUS DISEASE PRODUCTS BY TYPE AND DISEASE
VACCINE OPPORTUNITIES
PHARMACEUTICAL OPPORTUNITIES
THE EMERGENCE OF GENE THERAPY
MERGERS AND ACQUISITIONS
Chapter- 4: VACCINES-THE PRESENT AND THE FUTURE
MARKET FOR HUMAN INFECTIOUS DISEASE VACCINES
TYPES OF VACCINES
IMMUNITY
VIRAL DISEASES PREVENTED BY VACCINE
BACTERIAL DISEASES PREVENTED BY VACCINE
VACCINATION SCHEDULES FOR CHILDREN
CONCERNS REGARDING VACCINATION IN CHILDHOOD
VACCINE PRODUCTION
VACCINE MANUFACTURERS
TOP- SELLING VACCINES OF 2011
REGIONAL ANALYSIS
TRENDS IN VACCINE DEVELOPMENT
Chapter- 5: VIRAL INFECTIOUS DISEASES
GLOBAL MARKET FOR VIRAL INFECTIOUS DISEASE DIAGNOSTIC AND PHARMACEUTICAL
PRODUCTS
HEPATITIS B AND C
HERPES SIMPLEX VIRUS
HEPATITIS B AND C
HIV/AIDS
HUMAN PAPILLOMAVIRUS
INFLUENZA A AND B
MEASLES
PNEUMONIA
ROTAVIRUS
RSV
VIRAL DIAGNOSTIC PRODUCTS
VIRAL PHARMACEUTICAL PRODUCTS
Chapter- 6: BACTERIAL INFECTIOUS DISEASES AND THE SPECTER OF ANTIBIOTIC RESISTANCE
NEGLECTED TROPICAL BACTERIAL INFECTIOUS DISEASES
MARKET FOR BACTERIAL INFECTIOUS DISEASES DIAGNOSTIC AND PHARMACEUTICAL
PRODUCTS
MARKET FOR BACTERIAL INFECTIOUS DISEASE DIAGNOSTICS
MARKET FOR BACTERIAL INFECTIOUS DISEASES PHARMACEUTICALS
NOTABLE BACTERIAL DISEASES
ANTIBIOTIC DEVELOPMENT
ANTIBIOTIC RESISTANCE
PRIMARY REASONS FOR ANTIBIOTIC RESISTANCE
INTERNATIONAL SURVEILLANCE OF ANTIBIOTIC-RESISTANT ORGANISMS
RESISTANCE BY CLASS OF ANTIBIOTIC
INCIDENCES OF ANTIBIOTIC RESISTANCE
MAJOR ANTIBIOTIC-RESISTANT ORGANISMS
REGIONAL ANALYSIS
Chapter- 7: PARASITIC INFECTIOUS DISEASES
NEGLECTED TROPICAL PARASITIC INFECTIOUS DISEASES
CLIMATE CHANGE AND VECTOR-BORNE DISEASES
MALARIA
REGIONAL ANALYSIS
MARKET FOR ANTIPARASITIC PHARMACEUTICALS
Chapter- 8: EMERGING TECHNOLOGY AND PHARMACEUTICALS
HEPATITIS C
INFLUENZA
HSV
MALARIA
ANTIBIOTIC RESISTANCE
PHARMACEUTICAL TREATMENT PRODUCT PIPELINE
Chapter- 9: PATENT ANALYSIS
PHARMACEUTICAL PATENTS, BY PATENT NUMBER, DISEASE, COMPANY, DESCRIPTION
AND APPROVAL DATE
DIAGNOSTIC PATENTS ISSUED, BY COMPANY, APPROVAL DATE, AND DISEASE
Table 96 : INFECTIOUS DISEASES PHARMACEUTICAL AND VACCINE PATENTS, BY
PATENT NUMBER, DISEASE, COMPANY, PRODUCT DESCRIPTION AND APPROVAL DATE,
FEBRUARY 2006 TO FEBRUARY 2013
Table 97 : INFECTIOUS DISEASES DIAGNOSTIC PATENTS, BY PATENT NUMBER,
DISEASE, COMPANY, PRODUCT DESCRIPTION, AND APPROVAL DATE, MARCH 2005-DECEMBER
2012
Table 98 : INFECTIOUS DISEASES PHARMACEUTICAL, VACCINE, AND DIAGNOSTIC
PRODUCT PATENTS BY COMPANY, MARCH 2005-FEBRUARY 2013
Table 99 : INFECTIOUS DISEASE PRODUCT DIAGNOSIS, VACCINE AND TREATMENT
PATENTS BY COUNTRY, JANUARY 2005 TO FEBRUARY 2013
Table 100 : PATENTS ISSUED FOR DIAGNOSIS, VACCINE AND TREATMENT OF
INFECTIOUS DISEASES, BY DISEASE, MARCH 2005-FEBRUARY 2013
Table 101 : NUMBER OF INFECTIOUS DISEASES PATENTS FOR DIAGNOSTIC, VACCINE
AND PHARMACEUTICAL PRODUCTS, BY DISEASE AND YEAR, 2005-2013
Summary Figure : PERCENTAGE OF MARKET SHARE FOR INFECTIOUS DISEASE
DIAGNOSTIC, VACCINE AND PHARMACEUTICAL PRODUCTS BY GEOGRAPHIC REGION, 2012 AND
2017
Figure 1 : VACCINE-PREVENTABLE DEATHS IN CHILDREN UNDER FIVE YEARS OF AGE,
2008
Figure 2 : VACCINE MANUFACTURING PROCESS
Figure 3 : PERCENTAGE OF MARKET SHARE FOR VACCINES BY REGION, 2012 AND 2017
Figure 4 : TOP PHARMACEUTICAL MANUFACTURERS IN THE HEPATITIS MARKET AND
THEIR MARKET SHARE, 2011
Figure 5 : PERCENTAGE OF THE GLOBAL VIRAL DIAGNOSTIC AND PHARMACEUTICAL
MARKETS BY REGIONS, 2012 AND 2017
Figure 6 : MARKET SHARE OF BACTERIAL INFECTIOUS DISEASES DIAGNOSTIC AND
PHARMACEUTICAL PRODUCTS BY REGION, 2012 AND 2017
Figure 7 : GLOBAL MARKET FOR MALARIAL TREATMENTS BY REGION 2012 AND 2017
Figure 8 : NUMBER OF INFECTIOUS DISEASES PRODUCT DIAGNOSIS, VACCINE AND
TREATMENT PATENTS BY COUNTRY, JANUARY 2005-FEBRUARY 2013
Figure 9 : INFECTIOUS DISEASES DIAGNOSTIC, VACCINE AND PHARMACEUTICAL
PATENTS BY DISEASE ISSUED BETWEEN MARCH 2005 AND DECEMBER 2012,
Global Markets for Infectious Disease Treatments published by BCC Research in May 9, 2013. This report consists of 183 Pages and the price starts from US $ 5450.
The contents of this page may be different from the latest version. Please contact us for details.
